A pharmacokinetic approach to model-guided design of infliximab schedules in ulcerative colitis patients
Background: Infliximab, an anti-tumour necrosis factor approved for treatment of Crohn's disease and ulcerative colitis, is administered at predefined interdose-intervals. On insufficient response or loss of response, treatment can be intensified. The lack or loss of response is likely related...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Aran Ediciones
2015-03-01
|
| Series: | Revista Espanola de Enfermedades Digestivas |
| Subjects: | |
| Online Access: | http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-01082015000300003&lng=en&tlng=en |